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Metformin is the basic drug in the clinical treatment of Diabetes, often used 
in the treatment of Type 2 Diabetes Mellitus (T2DM).Its effect has been 
of T2DM with metformin, there is still a certain probability of related lactic 
acidosis, and the fatality rate is high. Therefore, is the use of metformin 
drug treatment a direct risk factor for lactic acidosis in diabetic patients? 
This paper will review the hypoglycemic mechanism of metformin and 
related studies on lactic acidosis, so as to further explore the relationship 
between metformin and lactic acidosis in diabetic patients, and provide 






Metformin is a widely used oral hypoglycemic drugs, 
have good hypoglycemic effect and the advantages of 
high safety, strong tolerance, be like the Chinese diabetes 
society (CDS), Japan diabetes association (JDA), and 
other academic organizations as type 2 diabetes (T2DM) 
than academic organization pointed out such as in patients 
without liver and kidney dysfunction and dose appropriate 
cases, metformin will always as a treatment of choice for 
patients with diabetes drug [1-3]. However, some studies 
have shown that taking metformin may be one of the caus-
es of lactic acidosis, with a mortality rate of up to 50% [4].
-
ten accompanied by one of the serious adverse reactions, 
clinical trials in recent years, studies have shown that 
doses of Metformin treatment result in the correlation of 
lactic Acidosis (MALA) cases are rare, but if the dose is 
too high, and not considering the circumstances of the 
body function in patients with abnormal could also lead 
to plasma lactic acid accumulation, and even cause cor-
relation lactic Acidosis (LA) [5]. This article will focus on 
the mechanism of metformin associated lactic acidosis 
(MALA) and its related factors to systematically review, 
in order to further clarify the relationship between the 
clinical use of metformin and diabetic lactic acidosis.
2. Hypoglycemic Mechanism of Metformin
Metformin is often combined with sulfonamide drugs 
in clinical use, which can effectively reduce blood glu-
-
betic patients, and the hypoglycemic effect is confirmed 
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2.1 Inhibition of Glucose Absorption and Promo-
tion of Glucose Utilization
The amount of blood sugar in human body mainly 
depends on the extent to which glucose is absorbed and 
utilized by tissues or organs. Glucose is absorbed mainly 
through the intestines. Glucose absorption by intestinal 
wall and other tissues is mainly through active transporta-
tion and glucose uptake by the carrier and ATP [7]. Several 
recent studies have shown that endotoxin derived from gut 
microbes may increase the disruption of intestinal barrier 
function and increase glucose uptake, leading to the devel-
opment of type 2 diabetes. Some studies have shown that 
[8]metformin can affect the microflora of mice and reduce 
the abundance of endotoxin-producing mucin-degrading 
G (-) anaerobes Akkermansia muciniphila in the intestinal 
tract of mice, thereby inhibiting excessive glucose absorp-
tion and thereby reducing the incidence of type 2 diabetes 
[9，10]. Glucose use is regulated mainly by hormones, the 
most important of which is insulin. Experimental results 
show that the oral metformin can improve mice to mice 
pancreas litres of blood sugar hormone kind of peptide 1 
(glp-1) content, but its mechanism is still unclear, glp-1 
have promote insulin secretion, enhance tissue sensitivity 
to insulin, alpha cells glucagon secretion inhibition, and 
by increasing the body’s insulin levels, in turn, promote 
the use of glucose [11-13]. Therefore, metformin, on the one 
hand, can reduce the absorption of glucose in the intesti-
nal wall, and on the other hand, it can promote the utiliza-
tion of glucose by regulating GLP-1 to increase the level 
of insulin.
2.2 Inhibition of Liver Glucose Output
In the regulation of human blood glucose, the liver 
plays an extremely important role in maintaining blood 
glucose balance. It can not only reduce blood glucose 
concentration through metabolic methods such as liver 
glycogen synthesis, but also increase blood glucose con-
centration through liver glycogen decomposition and glu-
coneogenesis. Metformin reduces liver glucose production 
primarily by adenosine activated protein kinase (AMPK). 
Main effect of metformin on the respiratory chain com-
plexes I to block the mitochondrial respiratory chain 
reducing intracellular ATP production, in turn, activates 
AMPK, its possible mechanism is: ① After metformin 
into cells, by influencing the LKB1 / AMPK signalling 
to reduce the concentration cAMP, promote response el-
ement binding protein 2 (CRCT2) phosphorylation, inhi-
bition of sugar dysplasia the expression of related genes, 
thereby reducing glycogenesis [14]. ② AMPK can activate 
liver deacetylase (SIRT1) and promote the acetylation and 
ubiquitination degradation of CRTC2, thereby inhibiting 
the transcription of genes related to gluconeogenesis [15]. 
③ Metformin activated AMPK upregulates the expression 
of orphan nuclear receptor (SHP), which competes for the 
binding site of CRTC2 and inhibits the formation of tran-
scriptional complexes, thereby inhibiting the expression 
of glycogenic related genes [14]. In addition, metformin 
can also reduce gluconeogenesis through other pathways, 
the possible mechanisms of which are as follows: ① Mi-
tochondrial respiratory chain is blocked by acting on re-
spiratory chain complex I and ATP production is reduced, 
and ATP has allosteric inhibition on key enzymes in 
glycolysis [16]. ② The decrease of ATP is accompanied by 
the increase of AMP, which inhibits the increase of blood 
glucose by inhibiting the glucagon signaling pathway [17].
③ Metformin directly inhibits mitochondrial glycer-
ol-3-phosphate dehydrogenase, enhances cytoplasmic 
reductive state, and inhibits the conversion of glycerol and 
lactic acid to glucose.
2.3 Improve Insulin Sensitivity and Insulin Resis-
tance (IR)
After absorption into blood, metformin can act on or-
gans around the liver, increase the number of insulin re-
ceptors and tyrosine kinase activity, and also improve the 
ability of insulin receptors and insulin binding, so as to 
improve the responsiveness of tissues and organs around 
the liver to insulin. Carolina et al. showed that when met-
formin was applied in clinical treatment, it could increase 
the insulin responsiveness of tissues and organs around 
the liver, so as to improve the utilization of glucose by 
tissue cells guided by hypoglycemic hormone [18]. Met-
formin also increases glucose transporter 4(GLUT-4) gene 
expression in skeletal muscle cells, thereby increasing the 
number and activity of GLUT-4 in skeletal muscle cells, 
thereby reducing peripheral insulin resistance (IR) [19]. In 
adipose tissue, metformin inhibits the phosphorylation 
of carbohydrate response element (ChREBP) and sterol 
binding element -1c (SREBP-1c) through AMPK signal-
ing pathway, promotes the reconversion of free fatty acids 
(FFA) to triglycerides and inhibits the decomposition of 
triglycerides. AMPK can also directly reduce acetyl-CoA 
carboxylase (ACC) activity and β-oxidation, thereby indi-
rectly improving IR [20].
3. Metguanidines and Lactic Acidosis
Lactic acidosis is a type of anion gap metabolic acido-
sis that occurs when lactic acid production is increased 
or metabolic pathways are blocked. When the disease is 
severe, it often involves multi-system organ function and 
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has a high-risk of death [21-22]. The hypoglycemic effect of 
guanidine drugs is mainly realized by inhibiting liver glu-
cose production and glucagon secretion and other mecha-
nisms. It can play a role in lowering blood glucose in di-
abetic patients with normal or abnormal insulin secretion, 
but has no significant lowering effect on blood glucose 
in non-diabetic patients [23]. The most common adverse 
reaction in the treatment of formin drugs is lactic acidosis, 
and MALA is a rare adverse reaction of metformin with a 
high fatality rate up to 50% [24], which is caused by the en-
hanced effect of formin drugs on the metabolism of reduc-
ing glucose. Metformin has been recognized as one of the 
first choice drugs for the treatment of type 2 diabetes due 
to its superior hypoglycemic effect, good tolerance and 
high safety. Metformin reduces lactic acid gluconeogen-
esis, thereby reducing the production of glucose, thereby 
accumulating lactic acid and thereby increasing the possi-
bility of lactic acidosis in diabetic patients [4,23,25].
In clinical studies, cases of MALA are rare. There have 
been reports of cases of LA in type 2 diabetic patients tak-
ing metformin, but these reports do not have a large num-
ber of data to show a clear causal relationship between 
metformin and lactic acidosis, and medical evidence is 
lacking. However, a large number of previous meta-anal-
yses have shown that the use of metformin has no signif-
icant correlation with the incidence of lactic acidosis and 
the mortality caused by lactic acidosis [23]. Previous studies 
have shown that MALA patients are often associated with 
secondary diseases that accelerate metabolic decompensa-
tion, usually infection, acute kidney, liver failure, or heart 
failure [26-28]. Although a possible role cannot be ruled out, 
most researchers agree that metformin does not consis-
tently correlate with the degree of acidosis. It is generally 
believed that the associated exacerbation of high-risk dis-
eases such as heart, kidney, and respiratory failure is the 
cause of the high mortality of lactic acidosis rather than 
the effect of metformin [29]. Scale et al. believed that com-
pared with metformin, the organic changes of tissues and 
organs caused by diabetes itself were more of a risk factor 
for LA, and the possible mechanism was that microvascu-
lar lesions caused by diabetes caused tissue hypoxia, thus 
increasing the risk of LA [30]. However, there are no sub-
stantial data showing a clear causal relationship between 
appropriate doses of metformin and lactic acidosis in pa-
tients without liver or kidney impairment.
3.1 Factors Influencing Metformin - Associated 
Lactic Acidosis (MALA)
As mentioned earlier, metaguanides are associated with 
an increased risk of lactic acidosis in diabetes treatment. 
However, due to the differences in molecular structure and 
chemical properties, metformin does not inhibit the release 
and metabolism of lactic acid. Therefore, the possibility 
of LA occurrence caused by metformin is much lower 
than that of other metformin drugs, and it is a relatively 
safe drug. According to many clinical studies, the occur-
rence of LA in the treatment of diabetes with metformin 
is very rare, and most of the cases are often accompanied 
by cardiopulmonary insufficiency, renal dysfunction and 
other diseases. Meanwhile, the incidence of lactic acidosis 
caused by metformin is also related to age and dosage [31].
3.2 Renal Insufficiency and MALA
Metformin is mainly excreted after the formation of 
water-soluble compounds through the treatment of oxi-
dative reducing water and other processes of the kidney. 
In general, metformin is mainly excreted through renal 
tubules, so as to ensure an appropriate level of metformin 
in the body. Thus, when renal function is normal, clinical 
treatment with medical doses of metformin does not re-
sult in lactic acidosis. When kidney dysfunction occurs, 
metformin cannot be effectively excreted, leading to 
metformin deposition in the body, which leads to elevated 
lactic acid levels in the body. Tian Hui et al. carried out an 
experiment, selected 243 elderly patients with T2DM, and 
observed the blood lactic acid level of patients before and 
after metformin alone, combined with other oral hypo-
glycemic agents or combined with insulin, and found that 
there was no statistical significance in the fluctuation of 
blood lactic acid content in patients, and no lactic acidosis 
event was observed [32]. Our guess is that severe kidney 
failure leads to a significant increase in lactate levels in 
the body.
3.3 Hypoxia and MALA
3.3.1 Cardiac Insufficiency and MALA
Most clinical studies have shown that the probability of 
metformin directly causing LA in patients is very small, 
while the probability of lactic acidosis in an anoxic state is 
sharply increased [33]. Diabetic patients are far more likely 
to suffer from heart failure than healthy people. If acute 
heart failure, myocardial infarction and other diseases 
occur in the body, it will lead to cardiac pumping dysfunc-
tion, which will lead to the decline of human circulation 
function, resulting in hypoxia of tissues and organs and 
lead to functional disorders. Therefore, the ability of im-
portant organs such as liver and kidney to remove lactic 
acid may decrease, and the lactic acid content may be 
affected and tends to rise, and even lactic acidosis may 
occur in the human body. Moreover, due to the increase 
of lactic acid accumulation, the K+ channel of cardiomyo-
DOI: https://doi.org/10.30564/jer.v3i1.2849
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cytes is stimulated to expand and the K+ outflow degree is 
increased. The adverse effect is inhibited on the Ca+ chan-
nel, resulting in the decrease of cellular ion concentration, 
and then the weakening of cardiac systolic function, form-
ing a chain of adverse reactions [34-35].
Therefore, metformin is often contraindicated for heart 
failure patients in clinical practice. Studies the selection 
of diabetes patients with heart failure in 1997-2006 (n 
= 10920), these patients through the use of metformin 
or sulfonylureas fall blood sugar, such as drug therapy, 
patients at the same time of voluntary participation in 
research study until the end of 2006, finally found a total 
of 6, 187 (57%) patients died, the process and no lactic 
acidosis patients in experimental [36]. Evans et al., Roussel 
et al., also reached the same conclusion in the same year 
[37,38]. Relevant literature has shown that metformin plays 
a certain role in antioxidant protection of cardiovascular 
disease [39]. Therefore, when the body does not have hy-
poxia caused by acute cardiac dysfunction, metformin can 
be used in patients with diabetes and cardiac dysfunction, 
but follow-up experimental studies are still needed to ver-
ify this.
3.3.2 Alcohol Intake and MALA
Long-term alcohol intake may lead to liver damage and 
even terminal liver disease. Liver is the main place for 
lactic acid metabolism, and metformin also causes the in-
crease of lactic acid by inhibiting the metabolism of lactic 
acid in the liver. Therefore, in the case of liver injury, the 
use of metformin will lead to the increase of lactic acid 
content in the body, leading to lactic acidosis. Krzymie ń, 
etc, according to a study in 29 patients with correlation 
lactic acidosis (8 cases of metformin treatment, 21 cases 
of other glucose-lowering drugs or treatment), 12 cases of 
alcoholic patients, 5 cases of death cases, 3 cases of met-
formin treatment, therefore the literature suggests that pa-
tients with diabetes with correlation of lactic acidosis with 
metformin use has no obvious relation, and with greater [40] 
the correlation of alcohol abuse. The specific mechanism 
is that alcohol stimulates the intestinal wall and produces 
a large amount of lactic acid accumulation, which needs 
to be transformed with the help of the liver. If the patient 
is alcoholized and the lesion involves the liver, ethanol 
metabolism in the liver cells has a synergistic effect with 
the conversion of pyruvate to lactic acid, and it can also 
inhibit the degree of glycoeogenesis of pyruvate. There-
fore, chronic alcoholism may impair liver parenchyma, 
thereby attenuate hepatic gluconeogenesis. Metformin 
has a similar effect to alcoholism, both promoting lactic 
acid production and preventing lactic acid metabolism [41]. 
They work in synergy. Therefore, heavy alcohol intake 
and chronic alcoholism may increase the incidence of 
MALA.
3.4 Age and MALA
With the increase of age, the liver and kidney functions 
of the elderly gradually decrease; meanwhile, the long-
term lesions of the microvessels in the elderly diabetic 
patients tend to cause hypoxia in the surrounding tissues, 
resulting in the increase of metformin and lactic acid con-
tent, which eventually leads to lactic acid accumulation 
and poisoning [33]. Based on the data analysis of 12 diabet-
ic patients with lactic acidosis caused by clinical treatment 
with metformin by Hua Zhong et al., it was shown that 
MALA was mainly characterized by older age, more liver 
and kidney insufficiency, irregular medication, etc [42,43]. 
Again, age was strongly associated with the incidence of 
MALA. Therefore, in the treatment of elderly diabetic pa-
tients, patients with serious liver and kidney dysfunction 
should be careful to take biguanidine drugs.
4. Summary and Prospect
A rare lactic acidosis occurs during the use of met-
formin. Is it metformin that is the culprit? Comb through 
the literature at home and abroad were reviewed, found 
that most of the research results show that has no direct 
correlation between metformin and lactic acidosis, at 
the same time a large number of clinical randomized 
controlled support metformin, there is no direct causal 
relationship between lactic acidosis and [44-45], but the real 
relationship also need to develop a large number of clin-
ical trials conducted in-depth research for them. What’s 
more, metformin can significantly increase the incidence 
of lactic acidosis when used in patients with liver and 
kidney insufficiency and heart failure. Although the inci-
dence of lactic acidosis is very low, the characteristics of 
high mortality still need to be paid attention to by clinical 
workers. Therefore, patients’ conditions, risk factors and 
physical conditions should be fully evaluated before the 
use of metformin in the treatment of patients, in order to 
effectively reduce the adverse reactions of metformin in 
the clinical treatment of diabetes, including metformin as-
sociated lactic acidosis (MALA).
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